Author:
Zheng N. X.,Sato H.,Adachi I.,Horikoshi I.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference21 articles.
1. Kanao M., Watanabe Y., Kimura Y. et al. (1989): Thromboxane A2 synthetase inhibitor. 2. Synthetes and activities of tetrahydronaphthalene and indan derivatives. J. Med. Chem., 32, 1326–1334.
2. Toda I., Nozaki A., Kawakubo K. et al. (1990): Effects of thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion. Jpn. Heart J., 31, 87–97.
3. Shimizu K., Kobayashi J., Iwanaga T., Kuratomi Y., Kitamura S. (1989): Effects of thromboxane A2 synthetase inhibitor, DP-1904, on the action of vasoactive substances in rabbit blood vessel smooth muscle preparations. Jpn. J. Thor. Dis., 27, 591–596.
4. Takami M., Takata Y., Matsumoto K., Ono S., Tsukada W. (1991): Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma, Ann. N.Y. Acad. Sci., 629, 407–409.
5. Masumura H., Kunitada S., Irie K., Ashida S., Abe Y. (1991): A thromboxane A2 synthetase inhibitor, DP-1904, prevents rat renal injury, Eur. J. Pharmacol., 193, 321–330.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic‐pharmacodynamic model;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-01-13
2. PK/PD Approach;Pharmacokinetics in Drug Discovery and Development;2002-03-06